Numerous Adverse Effects (numerous + adverse_effects)

Distribution by Scientific Domains

Selected Abstracts

Pulsed Signal Therapy® for the treatment of musculoskeletal conditions: a millennium paradigm

Abstract Reports and reviews from various sources, including the World Health Organization and United Nations Population Division, confirm the general increasing trend in the ageing population groups worldwide. There are over 150 types of musculoskeletal conditions, with rheumatoid arthritis, osteoarthritis, osteoporosis, low back pain and limb trauma, accounting for the greatest impact on the population at large. Osteoarthritis (OA) is predicted to become the fourth leading cause of disability by the year 2020. The most common medication prescribed for OA is non-steroidal anti-inflammatory drugs (NSAIDs). These have long been associated with numerous adverse effects, are costly and short-term in their ,therapeutic' effect. Pulsed Signal Therapy® (PSTÔ) is an innovative treatment modality for musculoskeletal conditions. It has been commercially available since 1992, is currently employed in at least 800 clinics and/or medical institutes, and to-date, no adverse effects have been reported. Furthermore, it is non-invasive, non-pharmacological, painless, with long-term follow-up, and sustained efficacy. When connective tissue is injured and physiological signalling is disturbed or absent, PSTÔ, as the external, biophysical signal (stimulus) of physiological energy parameters and waveform, passively induces ,fluid flow' in the injured area, creating ,streaming potentials', that induce biophysical-biochemical coupling, subsequent signal transduction, to activate repair and regenerative processes. In doing so, it restores the innate, physiological signalling to enable these regenerative and repair processes to continue naturally. [source]

Effects of HIV/AIDS on Maternity Care Providers in Kenya

Janet M. Turan
ABSTRACT Objective: To explore the impact of HIV/AIDS on maternity care providers in labor and delivery in a high HIV-prevalence setting in sub-Saharan Africa. Design: Qualitative one-on-one in-depth interviews with maternity care providers. Setting: Four health facilities providing labor and delivery services (2 public hospitals, a public health center, and a small private maternity hospital) in Kisumu, Nyanza Province, Kenya. Participants: Eighteen maternity care providers, including 14 nurse/midwives, 2 physician assistants, and 2 physicians (ob/gyn specialists). Results: The HIV/AIDS epidemic has had numerous adverse effects and a few positive effects on maternity care providers in this setting. Adverse effects include reductions in the number of health care providers, increased workload, burnout, reduced availability of services in small health facilities when workers are absent due to attending HIV/AIDS training programs, difficulties with confidentiality and unwanted disclosure, and maternity care providers' fears of becoming HIV infected and the resulting stigma and discrimination. Positive effects include improved infection control procedures on maternity wards and enhanced maternity care provider knowledge and skills. Conclusion: A multifaceted package including policy, infrastructure, and training interventions is needed to support maternity care providers in these settings and ensure that they are able to perform their critical roles in maternal healthcare and prevention of HIV/AIDS transmission. [source]

Presurgical intravenous parecoxib sodium and follow-up oral valdecoxib for pain management after laparoscopic cholecystectomy surgery reduces opioid requirements and opioid-related adverse effects

T. J. Gan
Background:, Opioids are associated with numerous adverse effects. It is unclear if reduced postoperative opioid consumption lowers the incidence and severity of opioid-related adverse effects. This analysis , from a multicenter, randomized, double-blind trial , tested if the reduction of opioid consumption among patients who received intravenous preoperative parecoxib 40 mg, followed by oral valdecoxib 40 mg qd postoperatively, in Days 1,4 after outpatient laparoscopic cholecystectomy surgery, reduced opioid-related symptoms. Methods:, Patients received intravenous fentanyl for pain before discharge, and oral acetaminophen 500 mg hydrocodone 5 mg q 4,6 h prn postdischarge for up to 7 days postsurgery. Patients also received intravenous parecoxib 40 mg administered 30,45 min preoperatively, and valdecoxib 40 mg qd up to Day 4 and prn Days 5,7 postsurgery, or placebo. Patients completed an opioid-related Symptoms Distress Scale (SDS) questionnaire every 24 h for 7 days. Opioid use was converted to morphine-equivalent doses (MEDs). Clinically meaningful events (CMEs) for 12 opioid-related symptoms were assessed by three ordinal measures: frequency, severity, and bothersomeness. Reduction of CMEs on Day 1 and number of patient-days with CMEs on Days 1,4 were examined. Results:, Cumulative MEDs on Day 0, Day 1, and Days 1,4 were significantly lower in the parecoxib/valdecoxib group compared with the placebo group (P < 0.001). At the end of Day 1, parecoxib/valdecoxib-treated patients had significantly lower SDS scores (P < 0.02), a significantly reduced incidence of CMEs (P < 0.05), and significantly fewer patient-days with CMEs in Days 1,4 than placebo patients (P < 0.05). Patients in the parecoxib/valdecoxib group were less likely to have CMEs for multiple symptoms than those in the placebo group (P < 0.001). Conclusions:, Treatment with parecoxib and valdecoxib significantly reduced the cumulative MED requirements, the incidence of opioid-related adverse effects, and patient-days with CMEs. [source]

Steroid avoidance using sirolimus and cyclosporine in pediatric renal transplantation: One year analysis

Franca M. Iorember
Iorember FM, Patel HP, Ohana A, Hayes JR, Mahan JD, Baker PB, Rajab A. Steroid avoidance using sirolimus and cyclosporine in pediatric renal transplantation: One year analysis. Pediatr Transplantation 2010: 14: 93,99. © 2009 John Wiley & Sons A/S. Abstract:, Steroids are commonly used in pediatric renal transplantation, but have numerous adverse effects. This retrospective study compares one-yr outcomes in 22 pediatric renal transplant recipients receiving SRL and CSA as primary immunosuppression (steroid-avoidance group) to age- and gender-matched historical controls receiving CSA, MMF, and prednisone (steroid group). At one yr, both groups had similar graft survival, acute rejection, and estimated GFR. Subjects in the steroid-avoidance group had better linear growth, less excessive weight gain and were less likely to have an increase in antihypertensive medication use. Subjects in the steroid-avoidance group were more likely to be started on lipid lowering medications and erythropoiesis stimulating agents. Despite having a greater proportion of living donors, the steroid-avoidance group had a similar GFR compared to the steroid group at one month. The steroid-avoidance group was also more likely to have a biopsy for elevated Cr that was not because of rejection and had more interstitial fibrosis noted. We conclude that using a steroid-avoidance immunosuppression regimen of SRL and CSA results in comparable rejection rates and short-term graft function with less steroid-associated morbidity. However, early findings also suggest possible potentiation of CSA nephrotoxicity by SRL in some children. [source]